Group 1 - The company has submitted an application for the initial public offering of H-shares to the Hong Kong Stock Exchange on September 22, 2025 [1][2] - The issuance will be limited to qualified foreign investors and domestic qualified investors under Chinese laws [2] - The application is subject to approval from regulatory bodies including the China Securities Regulatory Commission and the Hong Kong Stock Exchange, indicating uncertainty in the process [3] Group 2 - On September 22, 2025, the company's subsidiary signed a framework cooperation agreement with Ruipu Lanjun Energy Co., Ltd. for the supply of electrolyte products [5][11] - The agreement stipulates a minimum procurement volume of 800,000 tons of electrolyte products by Ruipu Lanjun until December 31, 2030 [5][11] - The agreement is expected to positively impact the company's operating performance from 2026 to 2030, enhancing its market share and profitability [13]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600872 证券简称：中炬高新 公告编号：2025-056 中炬高新技术实业（集团）股份有限公司 关于股东增持计划进展 暨权益变动触及1%刻度的提示性公告 中山火炬集团有限公司及其一致行动人中山火炬公有资产经营集团有限公司、上海鼎晖隽禺投资合伙企 业（有限合伙）、嘉兴鼎晖桉邺股权投资合伙企业（有限合伙）、CYPRESS CAMBO, L.P.保证向本公 司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ● 中炬高新技术实业（集团）股份有限公司（以下简称：中炬高新、公司）于2025年8月30日披露了 《中炬高新股东增持股份计划公告》（公告编号：2025-053），公司第一大股东中山火炬集团有限公司 （以下简称：火炬集团）拟自2025年9月1日起12个月内，通过上海证券交易所集中竞价交易等合法合规 方式增持中炬高新股份，拟增持金额不低于人民币2亿元，不超过人民币4亿元（以下简称：本次增持计 划）。 ● 本次权益变动系火炬集团实施本次增持计划，不触及要约 ...

Group 1 - The company held the 31st meeting of the 10th Supervisory Board on September 22, 2025, with all three supervisors present, and the meeting was chaired by Mr. Hong Gongxiang [2][4] - The Supervisory Board approved the proposal for the reduction of capital by Maanshan Iron & Steel Co., Ltd. in its associate company, Baowu Water Technology Co., Ltd., stating that the proposal aligns with the company's operational needs and strategic development [3][4] - The voting result for the proposal was unanimous approval with 3 votes in favor, 0 against, and 0 abstentions [4] Group 2 - The company announced that its controlling subsidiary, Maanshan Iron & Steel Co., Ltd., will reduce its capital in Baowu Water Technology Co., Ltd. through an asset valuation method, which constitutes a related party transaction [7][9] - The capital reduction agreement was signed on September 22, 2025, involving Maanshan Iron & Steel Co., Ltd. and 18 other shareholders, with the company's shareholding in Baowu Water decreasing from 14.977% to 3.151% [9][12] - The total equity value of Baowu Water was assessed at RMB 435.6 million, reflecting an increase of RMB 25.579 million, or 6.24%, compared to the book net asset value [12][13] Group 3 - The capital reduction will enhance the operational efficiency and effectiveness of Maanshan Iron & Steel Co., Ltd., and will not significantly impact its daily operations or financial status [14][16] - The independent directors reviewed and approved the capital reduction proposal, confirming that it aligns with the company's operational strategy and does not harm the interests of shareholders, especially minority shareholders [16][18] - The Board of Directors also approved the capital reduction proposal, with the related director abstaining from the vote, and the independent directors voting in favor [17][28]

证券代码：603588 证券简称：高能环境公告编号：2025-073 北京高能时代环境技术股份有限公司 ■ 本次解除质押股份暂无后续质押计划。李卫国先生后续将根据资金需求确定是否继续质押其所持有的公 司股份，并根据后续质押情况及时履行告知义务，公司将及时予以披露。 二、股东累计质押股份情况 本次解除质押后，李卫国先生累计质押股份情况如下： 关于控股股东、实际控制人部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 截至本公告披露日，北京高能时代环境技术股份有限公司（以下简称"公司"）控股股东、实际控制人 李卫国先生持有公司股份263,452,149股，约占公司总股本比例为17.30%。本次办理部分股份解除质押 后，李卫国先生累计质押股份数量为135,140,000股，约占其个人持有公司股份比例为51.30%。 ● 本次李卫国先生办理部分股份解除质押业务的无限售条件流通股合计7,000,000股，约占公司总股本比 例为0.46%，约占其个人持有公司股份比例为2.66%。 今日，公司接到控股 ...

Core Viewpoint - Anhui Conch Cement Co., Ltd. announced a cash dividend distribution of 0.24 RMB per share for the first half of 2025, approved by the board on August 26, 2025, following authorization from the annual general meeting on May 29, 2025 [2][4]. Summary by Sections Dividend Distribution Plan - The cash dividend of 0.24 RMB per share (before tax) will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the registration date [3][4]. - The total cash dividend to be distributed amounts to approximately 1.27 billion RMB, calculated based on the total share capital of 5,299,302,579 shares, excluding 22,242,535 shares held in the company's repurchase account [4][5]. Differentiated Dividend Distribution - The company will not issue bonus shares or increase capital from reserves; only cash dividends will be distributed [4][6]. - The reference price for the ex-dividend trading will be calculated based on the formula: (previous closing price - cash dividend) [5][6]. Taxation Information - Individual shareholders holding shares for over one year will be exempt from personal income tax on the dividends; those holding for one year or less will not have tax withheld at the time of distribution [8]. - For QFII shareholders, a 10% corporate income tax will be withheld, resulting in a net cash dividend of 0.216 RMB per share [9][10]. Implementation Details - The cash dividends will be distributed through the China Securities Depository and Clearing Corporation's clearing system, with specific arrangements for shareholders who have designated trading [6][7]. - The company will directly distribute cash dividends to its controlling shareholder, Anhui Conch Group [7].

登录新浪财经APP 搜索【信披】查看更多考评等级 股票代码：600123 股票简称：兰花科创公告编号：临2025-040 债券代码：138934 债券简称：23兰创01 债券代码：115227 债券简称：23兰创02 山西兰花科技创业股份有限公司 关于签订战略合作协议的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承 担个别及连带责任。 重要内容提示： ●近日，公司与上海盘毂动力科技股份有限公司签订了《战略合作协议》，本次战略合作协议是双方合 作意愿的意向性约定，具体合作内容及相关约定以后续签订的正式合作协议为准。 ●本协议的签署不涉及具体交易金额，对公司的影响需视双方合作实施情况而定。 ●公司将按照法律法规和《公司章程》的相关规定，对合作后续事项履行相应的审批程序和信息披露义 务，敬请广大投资者注意投资风险。 一、战略合作协议签署概况 为推动煤炭开采行业向智能化、高效化、绿色化转型，充分发挥双方核心优势，山西兰花科技创业股份 有限公司（以下简称 "公司" 或 "甲方"）与上海盘毂动力科技股份有限公司（以下简称 "乙方"）本 ...

Group 1 - The company disclosed the progress of performance commitments made by its shareholders, specifically the original controlling shareholders and their associates, in relation to a share transfer agreement signed on December 22, 2021 [1][2] - The relevant parties are actively promoting the performance commitment matters as per the share transfer agreement, and the company will comply with legal and regulatory disclosure requirements for any substantial progress [2] - The performance commitment is an agreement among shareholders that does not adversely affect the company's operational activities, and the company's production and operational status is currently normal [3]

Group 1 - The core point of the announcement is that shareholder Nie Weihua and his concerted actions have reduced their shareholding in Anhui Rongzhi Rixin Technology Co., Ltd. by 111,142 shares, which is 0.13% of the total share capital, bringing their total shareholding from 38.11% to 37.99% [2][3][4] - The reduction in shareholding occurred between September 18 and September 19, 2025, through centralized bidding transactions [2][3] - This change in equity does not trigger a mandatory tender offer and will not lead to changes in the company's controlling shareholder or actual controller [3][4] Group 2 - The reduction is part of a previously disclosed share reduction plan, which was announced on August 21, 2025 [3] - The company will continue to monitor the information disclosure obligations of the shareholder and ensure compliance with relevant regulations [4]

Group 1 - The announcement states that Chengdu Rongsheng Pharmaceutical Co., Ltd., a subsidiary of Beijing Tiantan Biological Products Co., Ltd., has received the Drug GMP Compliance Inspection Notice from the Sichuan Provincial Drug Administration [1][2] - The inspection was conducted from June 16 to June 19, 2025, and concluded that the production facility complies with the Drug Production Quality Management Standards (2010 revision) [2] - The inspected facility is focused on the production of therapeutic biological products, specifically the injection of recombinant human coagulation factor VIIa [1][2] Group 2 - The product "Injection of Recombinant Human Coagulation Factor VIIa" has completed Phase III clinical trials and has submitted a marketing authorization application, which is currently under review [3] - The receipt of the GMP Compliance Inspection Notice indicates that the production facility meets national GMP requirements, allowing for potential production upon obtaining the registration certificate and final production license for the product [3] - Future production of the product may be influenced by national policies and market conditions, indicating a level of uncertainty [3]

证券代码：600887 证券简称：伊利股份 公告编号：临2025-065 内蒙古伊利实业集团股份有限公司关于 2025年度第八期超短期融资券兑付完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 内蒙古伊利实业集团股份有限公司（简称"公司"）于2025年7月成功发行了2025年度第八期超短期融资 券，具体情况如下： ■ 2025年9月19日，公司完成了2025年度第八期超短期融资券的兑付工作，本息兑付总额为人民币 11,034,283,835.62元，由银行间市场清算所股份有限公司代理划付至债券持有人指定的银行账户。 特此公告 内蒙古伊利实业集团股份有限公司 董 事 会 ● 担保对象及基本情况 ■ ● 累计担保情况 ■ ● 本公告中担保金额折算汇率以2025年9月19日的汇率中间价计算：1欧元对人民币8.3834元 一、担保情况概述 （二）内部决策程序 二〇二五年九月二十三日 证券代码：600887 证券简称：伊利股份 公告编号：临2025-066 内蒙古伊利实业集团股份有限公司 关于为控股子公司提供担保的进展公告 本 ...